Seeking Alpha

Merck & Co Inc. (MRK)

  • Mar. 25, 2013, 5:29 AM
    The Supreme Court is due to hear a "pay for delay" a case today over whether it's legal for drug companies to pay generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The case is the FTC vs Actavis (ACT) and involves Abbott Labs' (ABT) AndroGel testosterone treatment. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation.
    | Mar. 25, 2013, 5:29 AM | 13 Comments
  • Mar. 15, 2013, 3:08 PM
    Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely shrugging off Cantor Fitzgerald's slashing of its price target to $4.00 from $11.00. The cut relates to ONTY's loss of Stimuvax. Cantor says that despite partner Merck's (MRK) assertion that treatment effects were observed in sub-populations, its financial model assumes that commercialization does not occur and no value is included in its valuation.
    | Mar. 15, 2013, 3:08 PM | Comment!
  • Mar. 15, 2013, 1:56 PM
    Cubist Pharmaceuticals (CBST -1.3%) slips on a less-than-stellar initiation at Credit Suisse with a Neutral rating and a $52 price target. The firm says it expects that positive CXA-201 data in the second half will strengthen confidence in the long-term sustainability of it's antibiotic franchise and be the impetus for global expansion.
    | Mar. 15, 2013, 1:56 PM | Comment!
  • Mar. 14, 2013, 5:48 PM
    The FDA is reviewing data on a certain class of diabetes drugs which it says might lead to precancerous changes in the pancreas. The drugs may include Eli Lilly's (LLY) Tradjenta, Merck's (MRK) Januvia, Novo Nordisk's (NVO) Victoza, and Bristol-Myers Squibb's (BMY) Byetta. Labels on the drugs already warn of increased potential for pancreatitis, which is the inflamation of the pancreas. The precancerous changes are new, and would affect future labeling.
    | Mar. 14, 2013, 5:48 PM | 4 Comments
  • Mar. 13, 2013, 11:52 AM
    Trius Therapeutics (TSRX +3.7%) moves up after reporting a Q4 loss that beat estimates. Revenue was also better, coming in at $5.2M, versus $5M the prior year. Net losses were higher, largely due to clinical and nonclinical development activities for tedizolid phosphate, our lead investigational drug in Phase 3 clinical development.
    | Mar. 13, 2013, 11:52 AM | 1 Comment
  • Mar. 13, 2013, 8:56 AM
    Luminex (LMNX) signs a deal to develop a diagnostic device that will help screen patients for recruitment into Merck's (MRK) clinical trials for MK-8931, its lead investigational candidate for Alzheimer's disease (AD). (PR)
    | Mar. 13, 2013, 8:56 AM | Comment!
  • Mar. 12, 2013, 4:26 PM
    Trius Therapeutics (TSRX): Q4 EPS of -$0.36 beats by $0.11. Revenue of $5.2M beats by $0.6M. (PR)
    | Mar. 12, 2013, 4:26 PM | Comment!
  • Mar. 12, 2013, 8:30 AM
    Merck (MRK +3.3%) says that the Data Safety Monitoring Board will allow the company to continue with its large-scale trial of its blockbuster Vytorin cholesterol drug, indicating that no safety issues have come up. Some analysts had hoped that the trial would already have demonstrated Vytorin's effectiveness and so could be halted. Alas, the study will continue until September 2014. (PR)
    | Mar. 12, 2013, 8:30 AM | Comment!
  • Mar. 10, 2013, 5:00 AM
    With companies looking to avoid paying taxes on their profits, 83 of the largest firms kept $1.46T overseas in 2012, up 14.4% from the previous year, Bloomberg calculates. GE (GE) again had the most with $108B held offshore, up from $102B in 2011; Pfizer was second with $73B, after which came Microsoft (MSFT), Merck (MRK), Johnson & Johnson (JNJ) and IBM (IBM).
    | Mar. 10, 2013, 5:00 AM | 73 Comments
  • Mar. 10, 2013, 4:24 AM
    Negative results from a major study of Merck's (MRK) cholesterol drug Tredaptive could spell the end of sales of AbbVie's (ABBV) Niaspan, which is an extended-release form of the niacin vitamin that sold $911M in 2012. Niacin is used in Tredaptive along with Merk's laropiprant; Tredaptive failed to reduce strokes, deaths and heart attacks in patients with vascular diseases but did cause increased side effects. (PR)
    | Mar. 10, 2013, 4:24 AM | Comment!
  • Mar. 4, 2013, 11:49 AM
    Bank of America Merrill Lynch makes a couple valuation calls in healthcare this morning, upping Merck (MRK +1.2%) to Buy on optimism over its osteoporosis drug, and moving to Neutral on Bristol-Myers (BMY -0.9%) due to its limited total-return potential.
    | Mar. 4, 2013, 11:49 AM | 1 Comment
  • Mar. 4, 2013, 9:50 AM
    Shares in GSK (GSK -0.6%), Pfizer (PFE +0.3%) and Abbott (ABT +0.2%) show little reaction to news that lamivudine and zidovudine, which they sell in a JV, helped cure a 2/12 year old infant of HIV. Other firms that develop HIV treatments, including Merck (MRK +0.4%), J&J (JNJ +0.35%) and Gilead (GILD +0.3%), also don't seem too impressed.
    | Mar. 4, 2013, 9:50 AM | Comment!
  • Feb. 28, 2013, 5:26 PM
    Cubist Pharmaceuticals (CBST) says the FDA has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product for the indications of Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections. Additionally, the FDA also granted the drugs Fast Track status for Complicated Intra-Abdominal Infections and Clostridium difficile-Associated Diarrhea. Shares +4% AH.
    | Feb. 28, 2013, 5:26 PM | Comment!
  • Feb. 26, 2013, 3:56 PM
    Merck & Co., Inc. (MRK) declares $0.43/share quarterly dividend, in line with previous. Forward yield 4.07%. For shareholders of record Mar. 15. Payable Apr. 05. Ex-div date Mar. 13. (PR)
    | Feb. 26, 2013, 3:56 PM | Comment!
  • Feb. 26, 2013, 1:58 PM
    Diabetes drugs sold by Merck & Co. (MRK -0.7%) and Bristol-Myers Squibb Co. (BMY +0.1%) may double a user’s risk of developing an inflammation of the pancreas linked to cancer and kidney failure, according to a recent study in the journal JAMA Internal Medicine. Analysis of insurance records indicate that patients hospitalized with pancreatitis were twice as likely to be taking Januvia, MRK’s top-selling drug, or BMY’s Byetta, than a control group of diabetics who didn’t have pancreatitis. Both drugs increase GLP-1, a hormone that stimulates insulin production from the pancreas.
    | Feb. 26, 2013, 1:58 PM | Comment!
  • Feb. 26, 2013, 9:51 AM
    Merck's (MRK +0.2%) and Bristol-Myers Squibb's (BMY +0.7%) multi-billion dollar diabetes drugs could double the risks of patients developing pancreatitis, which is an inflammation of the pancreas, a study indicates. Merck's Januvia and Bristol-Myers' Byetta increase GLP-1, a hormone that stimulates the pancreas' insulin output. Other drugs that do the same but weren't in study include Bristol's Onglyza and Novo Nordisk's (NVO) Victoza.
    | Feb. 26, 2013, 9:51 AM | Comment!
Visit Seeking Alpha's
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.